{
  "id": "cluster_8_doc1",
  "content": "Avalon Health Group reported increased claims for ketamine infusions among patients aged 35-50 with treatment-resistant depression in the Pacific Northwest region. Provider audits revealed inconsistencies in documentation standards across clinics, particularly at Cascade Behavioral Health. New preauthorization requirements will take effect November 15th.",
  "metadata": {
    "format": "insurance_memo"
  }
}